EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, Myeloma28 July 2022
Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, Myeloma19 October 2021
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosis23 June 2021
European Commission approves the second indication of isatuximab for relapsed multiple myelomaAccess, Myeloma19 April 2021
The FDA approves the first anti-BCMA CAR-T Cell Therapy for myeloma, idecabtagene vicleucel (Abecma)Access, Myeloma31 March 2021
Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, Myeloma30 March 2021
The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, Myeloma1 March 2021
Selinexor receives positive opinion from the EMA for the treatment of refractory myelomaAccess, Myeloma30 January 2021
Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosis17 January 2021
